BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype

IntroductionIndividuals with germline mutations in the BRCA1 gene have an elevated risk of developing breast cancer, and often display characteristic clinicopathological features. We hypothesised that inactivation of BRCA1 by promoter methylation could occur as a germline or an early somatic event that predisposes to breast cancer with the phenotype normally associated with BRCA1 germline mutation.MethodsWe examined seven cases from breast-ovarian cancer families with tumours that showed BRCA1-like pathology but did not have detectable BRCA1 or BRCA2 germline mutations present. Methylation levels were tested by several quantitative techniques including MethyLight, methylation-sensitive high resolution melting (MS-HRM) and a newly developed digital MS-HRM assay.ResultsIn one patient, methylation of 10% of the BRCA1 alleles was detected in the peripheral blood DNA, consistent with 20% of cells having one methylated allele. Buccal mucosa DNA from this individual displayed approximately 5% BRCA1 methylation. In two other patients, methylation of BRCA1 was detected in the peripheral blood at significantly lower but still readily detectable levels (approximately 1%). Tumour DNAs from these three patients were heavily methylated at BRCA1. The other patients had no detectable BRCA1 methylation in their peripheral blood. One of seven age-matched controls showed extremely low levels of methylation in their peripheral blood (approximately 0.1%).ConclusionThese results demonstrate that in some cases of breast cancer, low-level promoter methylation of BRCA1 occurs in normal tissues of the body and is associated with the development of BRCA1-like breast cancer.

[1]  G. Giles,et al.  The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations , 1998, Cancer.

[2]  J. Fridlyand,et al.  Lack of germ-line promoter methylation in BRCA1-negative families with familial breast cancer. , 2006, Genetic testing.

[3]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[4]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[5]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[6]  A. Richardson,et al.  BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles , 2005, Breast Cancer Research and Treatment.

[7]  S. Leung,et al.  Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer , 2006, Nature Genetics.

[8]  F. O'Malley,et al.  CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site , 1998, Oncogene.

[9]  E. Solomon,et al.  The 5' end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21. , 1996, Oncogene.

[10]  David I. K. Martin,et al.  Inheritance of a cancer-associated MLH1 germ-line epimutation. , 2007, The New England journal of medicine.

[11]  A. Dobrovic,et al.  Methylation of the BRCA1 gene in sporadic breast cancer. , 1997, Cancer research.

[12]  M. Stratton.  Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases , 1997, The Lancet.

[13]  Å. Borg,et al.  Tumour biological features of BRCA1-induced breast and ovarian cancer. , 1997, European journal of cancer.

[14]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Chenevix-Trench,et al.  Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. , 2000, Carcinogenesis.

[16]  I. Hedenfalk,et al.  Gene expression profiling of hereditary and sporadic ovarian cancers reveals unique BRCA1 and BRCA2 signatures. , 2002, Journal of the National Cancer Institute.

[17]  G. Giles,et al.  Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. , 1999, Cancer research.

[18]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[19]  Chun-Fang Xu,et al.  Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics , 1999, Oncogene.

[20]  Ana Osorio,et al.  A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  Megan Hitchins,et al.  MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. , 2005, Gastroenterology.

[22]  M. Loda,et al.  A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. , 2002, Cancer research.

[23]  K. Kinzler,et al.  Digital PCR. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  I. Andrulis,et al.  Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. , 2000, Carcinogenesis.

[25]  A. Dobrovic,et al.  Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation , 2007, Nucleic acids research.

[26]  D. Birnbaum,et al.  Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. , 1996, Cancer research.